Lyell Immunopharma Inc. (LYEL)
LYEL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1806952/000162828026017253/0001628280-26-017253-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LYEL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001806952 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $36K |
| Net income | -$274.4M |
| Operating income | -$269.4M |
| Net margin | -762355.6% |
| Operating margin | -748344.4% |
| Revenue growth | -41.0% |
| Cash | $60.2M |
| Total assets | $340.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 13028.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $92.1M cash; operating cash flow -$34.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 24,585,565 (2026-10-30); 21,218,217 a year earlier; 251,868,968 three years earlier. 3y figure adjusted for split (1-for-20 overall). | Cover page 2026-10-30 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2025-06-02 | Source 2025-06-02 |
| Shelf and offerings, 12 months | 4 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2025-12-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $12.5M, sold $605K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $3K | -$45.5M | -$34.6M | $92.1M | No debt tags | $15K | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $4K | -$44.8M | -$33.9M | $73.0M | No debt tags | $27K | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $2K | -$24.2M | -$38.5M | $90.8M | No debt tags | $31K | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $6K | -$140.7M | -$32.3M | $60.2M | No debt tags | $36K | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $15K | -$38.8M | -$28.6M | $123.6M | No debt tags | $41K | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $8K | -$42.7M | -$34.5M | $98.8M | No debt tags | $60K | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $7K | -$52.2M | -$54.7M | $120.3M | No debt tags | $65K | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $11K | -$191.9M | -$47.2M | $105.6M | No debt tags | $61K | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-13 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 365 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.8% |
| 1 month | +90.4% |
| 3 months | +4.1% |
| Year to date | -53.5% |
| 1 year | -17.9% |
| From 52-week high | -63.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OCS | Oculis Holding AG | $7.63 | -0.13% | $469.9M |
| KMDA | Kamada Ltd. | $8.11 | +0.25% | $468.0M |
| AQST | Aquestive Therapeutics Inc. | $3.76 | -3.84% | $472.6M |
| STTK | Shattuck Labs Inc. | $4.66 | +0.21% | $474.6M |
| PHAT | Phathom Pharmaceuticals Inc. | $5.88 | -2.97% | $478.0M |
| NGNE | Neurogene Inc. Common Stock | $23.30 | -2.63% | $482.3M |
| CAPR | Capricor Therapeutics Inc. | $8.30 | -12.91% | $482.6M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier